---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062859"
form_type: "8-K"
ticker: "GRML"
cik: "0001907223"
company_name: "Greenland Mines Ltd"
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:47:35.769509+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA grants Orphan Drug Designation for Klotho's KLTO-202 to treat ALS

## Summary
- FDA granted Orphan Drug Designation for KLTO-202 (s-KL-AAV.myo) for ALS.
- Designation provides tax credits for clinical trials, GDUFA fee waiver, and 7-year U.S. market exclusivity.
- Company completed proof-of-concept in two animal ALS models; initiating manufacturing and FDA/EMA meetings.
- KLTO-202 is a gene therapy using a muscle-specific desmin promoter to deliver secreted-Klotho protein.

## SEC filing metadata
- accession: 0001213900-25-062859
- form_type: 8-K
- ticker: GRML
- cik: 0001907223
- company_name: Greenland Mines Ltd
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907223/000121390025062859/0001213900-25-062859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907223/000121390025062859/ea0248604-8k_klotho.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062859
- JSON: https://secwatch.observer/filing/0001213900-25-062859.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.